Different administration routes of recombinant human endostatin combined with concurrent chemoradiotherapy might lead to different efficacy and safety profile in unresectable stage III non-small cell lung cancer: Updated follow-up results from two phase II trials.

ABSTRACT:

Background

There are two main choices of administration route of recombinant human endostatin (Endostar) available and the treatment options of concurrent chemoradiotherapy (CCRT) have changed over time. The aim of this study was to observe the long-term efficacy and safety of different administration routes of Endostar combined with CCRT.

Methods

Patients with unresectable stage III non-small cell lung cancer (NSCLC) from two phase II trials were included as two cohorts. Both were treated with Endostar combined with CCRT. Endostar was administrated by intravenous injection (7.5 mg/m² /day, seven days) in the IV arm and by continuous intravenous pumping (7.5 mg/m² /24 hours, 120 hours) in the CIV arm.

Results

A total of 48 patients were included

SUBMITTER: Honglian M 

PROVIDER: S-EPMC7113061 | biostudies-literature | 2020 Apr

REPOSITORIES: biostudies-literature